FDA Clears Cosentyx for Polymyalgia Rheumatica, Roche's Wilserdly for ESR1-Mutated Breast Cancer
FDA approved Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica and Roche's Wilserdly after a 62% risk reduction, while Gilead licensed obeldesivir across 127 countries.
